Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations.
Yuji UeharaKageaki WatanabeTaiki HakozakiMakiko YomotaYukio HosomiPublished in: Thoracic cancer (2022)
The benefit of the first-line ICI was similar in advanced NSCLC regardless of the driver alterations, except for MET alterations.